Breaking News
Latest COVID-19 Outbreak Information and Resources
As a part of our efforts to protect the health of our employees, US Equestrian is working under a flexible work plan for our staff. As we transition to this modified format, there may be interruptions to service. We will do our best to have all services fully functioning as quickly as possible. Customer Care can be reached by emailing [email protected], online chat or leave a voicemail by calling (859) 258-2472. Thank you in advance for your understanding and patience.
  • Share:

US Equestrian Announces Requirements for Use of FDA-Approved Zimeta™ (Dipyrone Injection)

by US Equestrian Communications Department | Dec 31, 2019, 12:00 PM EST

Lexington, Ky. - Kindred Biosciences, Inc. announced the drug, Zimeta™ (dipyrone injection), has been approved for use in horses for the control of pyrexia (fever) by the U.S. Food and Drug administration’s Center for Veterinary Medicine.

Dipyrone is a non-steroidal anti-inflammatory drug (NSAID); however, it is not one of the seven quantitatively restricted NSAIDs currently addressed by USEF Equine Drugs and Medications Rules. As such, it is a prohibited substance, but GR411 (Conditions For Therapeutic Administrations of Prohibited Substances) will apply. Any use of Zimeta™ (dipyrone injection) will require a properly filed medication report form documenting a 24-hour withdrawal. Additionally, the administration of dipyrone will not constitute the use of a second NSAID, which is prohibited by USEF rules. This policy is effective immediately.

For questions, please call the USEF Equine Drugs and Medications Program at 800-633-2472.